神威药业(02877.HK)首九个月营业额录18.8亿人币 按年减8.3%
神威药业(02877.HK)公布,今年首九个月,营业额录18.8亿元人民币(下同),按年减少8.3%。当中,注射液产品、颗粒剂产品及其他剂型产品的营业额分别跌17.4%、7.3%及18.9%,软胶囊产品及中药配方颗粒产品则分别增0.5%及8.7%。
单计第三季度,神威药业整体营业额录得1.1%增长。注射液产品、软胶囊产品及颗粒剂产品的销售均录跌幅,分别跌1.2%、10.4%及4.3%,而中药配方颗粒产品则按年增25.4%。
以产品剂型分析,注射液产品、软胶囊产品、颗粒剂产品及中药配方颗粒产品分别占集团之营业总额约41.9%、18.8%、12.8%及21.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.